Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National Medicare Analysis Opened For Watchman Device

This article was originally published in The Gray Sheet

Executive Summary

CMS will consider a national policy for the left atrial appendage closure device in response to a request from Boston Scientific.

You may also be interested in...



Voices From TCT 2015: Ken Stein On The Future Of Watchman

In an exclusive podcast interview with "The Gray Sheet," Ken Stein, Boston Scientific's chief medical officer for cardiac rhythm management, says the company is well positioned to expand adoption of its novel Watchman left-atrial appendage closure device after a challenging regulatory process. He says CMS' recent denial of a new-technology add-on payment is actually good news for the device and the company is looking forward to that agency establishing a national coverage policy.

Drug-Coated Balloons Net Medicare Inpatient Bonus Payments

The positive hospital inpatient reimbursement decision for recently launched Medtronic and CR Bard peripheral artery devices follows prior positive policy rulings in the outpatient setting. Meanwhile, CMS rejected Boston Scientific's new-technology add-on application for the Watchman stroke device, but the agency did establish a pricier payment category for the new procedure.

Cardiology Societies Urge Registry For Left-Atrial Appendage Closure Devices

The American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions released an overview of left atrial appendage occlusion devices, specifically Boston Scientific's Watchman and SentreHEART's Lariat.

Related Content

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel